178 related articles for article (PubMed ID: 1884741)
21. Comparative pharmacokinetics of oral 6-mercaptopurine and intravenous 6-mercaptopurine riboside in children.
Mawatari H; Unei K; Nishimura S; Sakura N; Ueda K
Pediatr Int; 2001 Dec; 43(6):673-7. PubMed ID: 11737747
[TBL] [Abstract][Full Text] [Related]
22. Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1.
Landier W; Hageman L; Chen Y; Kornegay N; Evans WE; Bostrom BC; Casillas J; Dickens DS; Angiolillo AL; Lew G; Maloney KW; Mascarenhas L; Ritchey AK; Termuhlen AM; Carroll WL; Relling MV; Wong FL; Bhatia S
J Clin Oncol; 2017 May; 35(15):1730-1736. PubMed ID: 28339328
[TBL] [Abstract][Full Text] [Related]
23. Importance of 6-mercaptopurine dose in lymphoblastic leukaemia.
Hale JP; Lilleyman JS
Arch Dis Child; 1991 Apr; 66(4):462-6. PubMed ID: 2031601
[TBL] [Abstract][Full Text] [Related]
24. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.
Lennard L; Lilleyman JS; Van Loon J; Weinshilboum RM
Lancet; 1990 Jul; 336(8709):225-9. PubMed ID: 1973780
[TBL] [Abstract][Full Text] [Related]
25. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM;
Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
[TBL] [Abstract][Full Text] [Related]
26. Extremely low dose of 6-mercaptopurine in a Chinese child with acute lymphoblastic leukaemia and multiple pharmacogenetic mutations.
Zhai XY; Zhou Y; Dong L; Nie AQ; Zhi LJ; Jacqz-Aigrain E; Wang TY; Wang L; Zhao W
J Clin Pharm Ther; 2021 Feb; 46(1):74-77. PubMed ID: 32893890
[TBL] [Abstract][Full Text] [Related]
27. Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia.
Koren G; Langevin AM; Olivieri N; Giesbrecht E; Zipursky A; Greenberg M
Am J Dis Child; 1990 Oct; 144(10):1135-7. PubMed ID: 2403095
[TBL] [Abstract][Full Text] [Related]
28. Cranial irradiation and cerebrospinal fluid levels of 6-mercaptopurine in children with acute leukemia.
Riccardi R; Lasorella A; Tartaglia RL; Riccardi A; Servidei T; Mastrangelo R
Med Oncol Tumor Pharmacother; 1991; 8(2):95-8. PubMed ID: 1749306
[TBL] [Abstract][Full Text] [Related]
29. Compliance with oral chemotherapy in childhood lymphoblastic leukaemia.
Davies HA; Lilleyman JS
Cancer Treat Rev; 1995 Mar; 21(2):93-103. PubMed ID: 7758006
[No Abstract] [Full Text] [Related]
30. 6-Mercaptopurine in cerebrospinal fluid during oral maintenance therapy of children with acute lymphoblastic leukemia.
Hayder S; Lafolie P; Björk O; Ahström L; Peterson C
Med Oncol Tumor Pharmacother; 1988; 5(3):187-9. PubMed ID: 3166086
[TBL] [Abstract][Full Text] [Related]
31. Disposition of oral methotrexate in children with acute lymphoblastic leukemia and its relation to 6-mercaptopurine pharmacokinetics.
Koren G; Solh H; Klein J; Soldin SJ; Greenberg M
Med Pediatr Oncol; 1989; 17(6):450-4. PubMed ID: 2586358
[TBL] [Abstract][Full Text] [Related]
32. Detection and identification of 6-methylmercapto-8-hydoxypurine, a major metabolite of 6-mercaptopurine, in plasma during intravenous administration.
Keuzenkamp-Jansen CW; van Baal JM; De Abreu RA; de Jong JG; Zuiderent R; Trijbels JM
Clin Chem; 1996 Mar; 42(3):380-6. PubMed ID: 8598099
[TBL] [Abstract][Full Text] [Related]
33. Determination of 6-mercaptopurine in acute lymphoblastic leukemia patients' plasma by high-performance liquid chromatography.
Kato Y; Matsushita T; Yokoyama T; Mohri K
Ther Drug Monit; 1991 May; 13(3):220-5. PubMed ID: 1926275
[TBL] [Abstract][Full Text] [Related]
34. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations.
Lancaster DL; Lennard L; Rowland K; Vora AJ; Lilleyman JS
Br J Haematol; 1998 Jul; 102(2):439-43. PubMed ID: 9695957
[TBL] [Abstract][Full Text] [Related]
35. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
[TBL] [Abstract][Full Text] [Related]
36. 6-Thioguanine nucleotide accumulation in red blood cells during maintenance chemotherapy for childhood acute lymphoblastic leukemia, and its relation to leukopenia.
Schmiegelow K; Bruunshuus I
Cancer Chemother Pharmacol; 1990; 26(4):288-92. PubMed ID: 2369793
[TBL] [Abstract][Full Text] [Related]
37. Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance?
Lennard L; Welch J; Lilleyman JS
Br J Cancer; 1995 Oct; 72(4):1004-6. PubMed ID: 7547211
[TBL] [Abstract][Full Text] [Related]
38. Mercaptopurine in childhood leukaemia: the effects of dose escalation on thioguanine nucleotide metabolites.
Lennard L; Welch J; Lilleyman JS
Br J Clin Pharmacol; 1996 Oct; 42(4):525-7. PubMed ID: 8904630
[TBL] [Abstract][Full Text] [Related]
39. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine.
Balis FM; Holcenberg JS; Zimm S; Tubergen D; Collins JM; Murphy RF; Gilchrist GS; Hammond D; Poplack DG
Clin Pharmacol Ther; 1987 Apr; 41(4):384-7. PubMed ID: 3470165
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of oral 6-mercaptopurine: relationship between plasma levels and urine excretion of parent drug.
Endresen L; Lie SO; Storm-Mathisen I; Rugstad HE; Stokke O
Ther Drug Monit; 1990 May; 12(3):227-34. PubMed ID: 2349605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]